CompletedPhase 3NCT03572933

Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

Studying CDKL5-deficiency disorder

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Marinus Pharmaceuticals
Principal Investigator: Joseph Hulihan, MD, M.D
Marinus Pharmaceuticals, Inc.
Intervention: ganaxolone(drug)
Enrollment: 101 enrolled
Eligibility: 2-21 years · All sexes
Timeline: 2018 – 2021

Study locations (30)

Marinus Research Site, Phoenix, Arizona, United States
Marinus Research Site, Los Angeles, California, United States
Marinus Research Site, Aurora, Colorado, United States
Marinus Research Site, Gulf Breeze, Florida, United States
Marinus Research Site, Orlando, Florida, United States
Marinus Research Site, Norcross, Georgia, United States
Marinus Research Site, Chicago, Illinois, United States
Marinus Research Site, Iowa City, Iowa, United States
Marinus Research Site, Boston, Massachusetts, United States
Marinus Research Site, Rochester, Minnesota, United States
Marinus Research Site, St Louis, Missouri, United States
Marinus Research Site, Livingston, New Jersey, United States
Marinus Research Site, Cleveland, Ohio, United States
Marinus Research Site, Philadelphia, Pennsylvania, United States
Marinus Research Site, Pittsburgh, Pennsylvania, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03572933 on ClinicalTrials.gov

Other trials for CDKL5-deficiency disorder

Additional recruiting or active studies for the same condition.

See all trials for CDKL5-deficiency disorder →

← Back to all trials